FK506 binding protein 51 (FKBP51), a member of the immunophilin family, is involved in multiple signaling pathways, tumorigenesis, and chemoresistance. FKBP51 expression correlates with metastatic potential in melanoma and prostate cancer. However, the functions of FKBP51, particularly involving the regulation of cell motility and invasion, are not fully understood. We discovered two novel interacting partner proteins of FKBP51, i.e., deleted in liver cancer 1 (DLC1) and deleted in liver cancer 2 (DLC2), using immunoprecipitation and mass spectrometry. DLC1 and DLC2 are Rho GTPase-activating proteins that are frequently downregulated in various cancers. Next, we demonstrated that overexpression of FKBP51 enhances cell motility and invasion of U2OS cells via upregulation of RhoA activity and enhanced Rho-ROCK signaling. Moreover, FKBP51-depleted cells displayed a cortical distribution of actin filaments and decreased cell motility and invasion. Consistent with this phenotype, FKBP51 depletion caused a downregulation of RhoA activity. Considered together, our results demonstrate that FKBP51 positively controls cell motility by promoting RhoA and ROCK activation; thus, we have revealed a novel role for FKBP51 in cytoskeletal rearrangement and cell migration and invasion.
FK506 binding protein 51 (FKBP51), a member of the immunophilin family, is involved in multiple signaling pathways, tumorigenesis, and chemoresistance. FKBP51 expression correlates with metastatic potential in melanoma and prostate cancer. However, the functions of FKBP51, particularly involving the regulation of cell motility and invasion, are not fully understood. We discovered two novel interacting partner proteins of FKBP51, i.e., deleted in liver cancer 1 (DLC1) and deleted in liver cancer 2 (DLC2), using immunoprecipitation and mass spectrometry. DLC1 and DLC2 are Rho GTPase-activating proteins that are frequently downregulated in various cancers. Next, we demonstrated that overexpression of FKBP51 enhances cell motility and invasion of U2OS cells via upregulation of RhoA activity and enhanced Rho-ROCK signaling. Moreover, FKBP51-depleted cells displayed a cortical distribution of actin filaments and decreased cell motility and invasion. Consistent with this phenotype, FKBP51 depletion caused a downregulation of RhoA activity. Considered together, our results demonstrate that FKBP51 positively controls cell motility by promoting RhoA and ROCK activation; thus, we have revealed a novel role for FKBP51 in cytoskeletal rearrangement and cell migration and invasion.
T he FK506 binding protein FKBP51 (also referred as FKBP5) is highly expressed in prostate cancer, lymphoma, and melanoma; furthermore, FKBP51 expression correlates with metastatic potential in melanoma and prostate cancer, and its silencing restores resistance to apoptosis in these two cancers.
(1-7) FKBP51 promotes melanoma growth by modulating TGF-b expression and activating NF-jB, which induces interleukin-8 (IL-8). (3) (4) (5) Moreover, FKBP51 acts as an anti-apoptotic factor in cancer development and progression by enhancing the telomerase activity of hTERT. (6) FKBP51 controls androgen-dependent growth of prostate cancer by enhancing activity of androgen receptor transcription. (8) (9) (10) By contrast, some reports have shown that FKBP51 functions as a tumor suppressor. (11, 12) The expression of FKBP51 is downregulated in pancreatic and colon cancer. FKBP51 and PH domain leucine-rich repeat protein phosphatase (PHLPP) influence the kinase activity of Akt by acting as a scaffold complex that promotes the dephosphorylation of Akt. (11) FKBP51 knockdown in a xenograft mouse model that produced a significant increase in tumor burden when compared with wild type mice. (12) Thus, both the overexpression and downregulation of FKBP51 have been detected in several human cancers.
FKBP51 is also an immunophilin co-chaperone for the heat shock protein 90 (Hsp90) molecular chaperone machine and has been identified as an important component of steroid hormone receptor-Hsp90 heterocomplexes. (13) (14) (15) FKBP51 is a regulator of glucocorticoid and progesterone receptor signaling (16) (17) (18) and was recently shown to interact with the androgen receptor (AR) and estrogen receptor (ER). (19) This study explores a novel role for FKBP51. To this end, we attempted to identify new FKBP51 targeting proteins via a mass spectrometry analysis of anti-FKBP51 immunoprecipitates from MCF7 cells. We identified deleted in liver cancer 1 (DLC1, also known as ARHGAP7 and STARD12) and deleted in liver cancer 2 (DLC2/ARHGAP37/STARD13), which are structurally similar and share the same functional domains (sterile a motif (SAM), Rho-GAP, and START domains). (20) (21) (22) (23) Both proteins are underexpressed in certain cancers, and they suppresses tumor cell growth by inhibiting RhoA activity via the Rho-GAP domain. (24) (25) (26) (27) Their Rho-GAP activity strongly hydrolyzes Rho-GTP, weakly hydrolyzes Cdc42-GTP, and has no detectable activity against Rac-GTP. (28, 29) We determined that overexpression of FKBP51 increased the active GTP-bound state of the RhoA protein. GTP-RhoA has a critical role in cell motility and invasion via actin remodeling. (30, 31) Consistent with our hypothesis, depletion of FKBP51 impaired RhoA activation and decreased cell motility and invasion via perturbation of cytoskeleton. Thus, we newly report that FKBP51 regulates RhoA activation via interactions with DLC proteins. and Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) as described by the manufacturer.
Immunoprecipitation and Western blot analysis. Immunoprecipitation and Western blotting were performed as previously described. (32) The following antibodies were used for immunoprecipitation: FKBP51 (sc-271547; Santa Cruz Biotechnology), StARD13 (HPA035535; Sigma), and Halo (G9281; Promega). The following primary antibodies were used for immunoblotting: FKBP51 (ab126715; Abcam, Cambridge, UK and A301-430A; Bethyl Laboratories, Inc., Montgomery, TX, USA), StARD13 (HPA035535; Sigma), Halo (G9281; Promega), and b-actin (Sigma). Horseradish peroxidase-conjugated secondary antibodies (Amersham Biosciences, Amersham, UK) were used to detect immunoreactive proteins by enhanced chemiluminescence (Thermo Scientific, Waltham, MA, USA).
Immunofluorescence microscopy. The cells were fixed with 3.7% formaldehyde in phosphate-buffered saline (PBS) for 10 min on ice and permeabilized sequentially with 50%, 75%, and 95% ethanol on ice for 5 min each. The slides were blocked with a PBS-containing blocking solution for 30 min at room temperature and then incubated with the primary antibodies, anti-Cortactin and phalloidin-Atto 565 (Sigma-Aldrich) for 1 h at room temperature. Slides were then washed three times with PBS for 5 min each and incubated with an Alexa488 secondary antibody (Molecular Probes, Eugene, OR, USA) for 30 min at 37°C. After washing twice with PBS, DNA was stained with 1 lg/mL of bisbenzimide (Hoechst 33258) in the final PBS wash. The samples were examined using a TCS SP8 and AF6000 confocal microscope (Leica Microsystems, Wetzlar, Germany). USA) were extracted from the resulting data. The peptide enrichment ratio was calculated to evaluate the certainty of peptide identification. Wound-healing assay. Confluent cell monolayers were wounded (lightly scratched) with a pipet tip. After careful washing to remove detached cells, the cells were cultured for 24 h. Phase-contrast images were taken every 30 min for 24 h. The width of the wound was monitored using an FW4000-TZ time-lapse microscope (Leica Microsystems). For the ROCK inhibitor (Y27632) assay, cells were treated with the inhibitor (50 lM) for 24 h and then wounded. Phase-contrast images were taken immediately after scratching (0 h) and 5 h later.
Cell invasion assays. Cell invasion assays were conducted with a CytoSelect 96-well cell invasion assay kit according to the manufacturer's protocol. A total of 1.5 9 10 5 cells in serum-free medium were harvested from a 96-well cell invasion plate from the basement membrane layer. The plate was then placed in an incubator at 37°C in 5% CO 2 for 24 h. Next, the membrane chamber was transferred to the Cell Harvesting Tray containing a cell detachment solution. The invasion cells were stained with a CyQuant GR dye solution, and absorbance at 480/520 nm was measured with a microplate reader.
RhoA activation assay. RhoA activation was assessed with a Rho Activation Assay Biochem Kit according to the manufacturer's protocol. Full-length FLAG-FKBP51 and RhoA-Halo proteins were expressed in 293T cells. GTP-RhoA was isolated from cell extracts using glutathione-sepharose beads coated with a rhotekin Rho binding domain (RBD) expressed as a GST fusion. An equal volume of cell lysate was incubated with Rhotekin-RBD Protein Beads at 4°C for 1 h. Next, the beads were rinsed with wash buffer. The samples were eluted and subjected to Western blotting with anti-RhoA. ROCK activity assay. U2OS cells were transfected with FLAG-FKBP51 or mock (FLAG) vector in medium with 10% FBS for 48 h at 37°C and 5% CO 2 . After PBS washes, the cells were suspended in a sonication buffer (50 mM Tris-HCl, pH 8.0, 1 mM ethylenediaminetetraacetic acid [EDTA], 1 mM EGTA) containing protease inhibitors (Sigma-Aldrich). The samples were then processed with sonication for 15 s followed by centrifugation (14 000 g for 30 min) to obtain cell extract. The protein content was determined using a protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). The crude extracts were applied to a HiTrap Q HP column (GE Healthcare Life Science, Buckinghamshire, UK) that was equilibrated with Q-buffer (20 mM Tris-HCl, pH 8.0, 0.5 mM EDTA, 1 mM EGTA, 5 mM beta-glycerophosphate, 2 mM NaF, 2 mM Na 3 VO 4 , 5 mM beta-mercaptoethanol) containing 50 mM NaCl. The protein was eluted with a linear gradient of NaCl (0.05-0.6 M) in Q-buffer. The collected 1-mL fractions were then washed with Q-buffer. ROCK protein in fractions were detected with immunoblotting using an anti-ROCK1 antibody. ROCK activity was measured using the fraction containing ROCK1 with a Cyclex Rho-kinase Assay Kit (MBL, Nagoya, Japan) according to the manufacturer's protocol. The inhibitory effect of the ROCK inhibitor on ROCK activity was evaluated with the direct addition of Y27632 (10 lM) to the ROCK1 fraction. The kinase activity in the vehicle control was defined as 1 (n = 3).
Statistical analysis. A Student's t-test was used to evaluate the data from the proliferation, migration, and invasion assays.
P-values of <0.05 were considered statistically significant. All statistical analyses were performed using SPSS software (IBM, Armonk, NY, USA).
Results
Analysis of FKBP51-binding proteins using mass spectrometry. To identify new FKBP51-binding partners, we subjected lysates prepared from MCF7 cells to immunoprecipitation with an anti-FKBP51 antibody. Immunoprecipitated protein complexes were subjected to SDS-PAGE and analyzed by CBB staining (Fig. 1a) . Bands distinct from the control were cut and digested with trypsin and then analyzed by tandem mass spectroscopy LC/MS/MS (QTRAP 5500 system). Analysis of the tryptic peptides revealed the presence of DLC1 (ARH-GAP7/STARD12), DLC2 (ARHGAP37/STARD13), the glucocorticoid and progesterone receptors, and Hsp90 proteins, including FKBP51 (Fig. 1b and Fig. S1a ). These proteins were not detected in the samples immunoprecipitated with normal rabbit IgG. The glucocorticoid receptor, progesterone receptor, and Hsp90 are known to interact with FKBP51, which functions as a co-chaperone with Hsp90 for glucocorticoid and progesterone receptors. The immunoprecipitation of MCF7 cell lysates using the anti-DLC2 antibody detected the FKBP51 protein (Fig. 1c ). DLC1 and 2 show GAP activity that specifically inhibits RhoA function. The Rho-GAP domain is highly conserved between DLC1 (residues 1078-1284) and DLC2 (residues 663-867) (Fig. S1b) . These results suggest that both DLC proteins, which exhibit high homology in their GAP domains, are novel FKBP51-associated proteins.
Overexpression of FKBP51 influences Rho-GAP activity. Given that FKBP51 and DLCs (1 and 2) associate in cells, we Halo-RhoA for 24 h followed by treatment with siRNA-FKBP51 or siRNA-control for 48 h. Cells were then subjected to the RhoA activation assay. We completed a Western blot analysis of the pulleddown activated forms of RhoA after depletion of FKBP51. (b) The corresponding quantification of independent pull-down experiments is shown (normalization of the GTP-bound forms to total RhoA). Column graphs are represented as the mean AE SEM (n = 3; siRNA-FKBP51 and siRNAcontrol for the RhoA pull-down assay). (c) Cells expressing endogenous FKBP51 or Halo-DLC2 were visualized by anti-FKBP51 and anti-Halo antibodies. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control.
speculated that FKBP51 affects GAP activity. To determine whether FKBP51 influences Rho-GAP activity, we examined GAP assays using recombinant proteins. GTP-RhoA was assessed semiquantitatively by Western blotting, and the data were used to calculate Rho activation [(GTP-RhoA/Total RhoAHalo) 9 100] (Fig. 2a) . Cells expressing FLAG-FKBP51 or Halo-DLC2 were visualized with anti-Halo and anti-FLAG antibodies (Fig. 2b) . Western blot analysis revealed an approximate 2.5-fold increase in Rho activation in FLAG-FKBP51-overexpressing 293T cells when compared with FLAG overexpressing control cells (Fig. 2a,c; lanes 1 and 2) . By contrast, Rho activation in Halo-DLC2-overexpressing 293T cells was decreased when compared with control cells (Fig. 2a; lanes 2 and 3) . These results suggest that the interaction of FKBP51 with GAP proteins decreases GAP activity, thus increasing GTP-RhoA expression.
Overexpression of FKBP51 enhances cells motility and invasion. To determine whether FKBP51 overexpression correlates with cell motility and invasion, we expressed FLAG-FKBP51 in U2OS cells (Fig. S2a) . Cell numbers were measured using a water-soluble tetrazolium-1 (WST-1) assay. The relative fluorescence units (RFU) indicate the relative level of proliferation. Column graphs show the mean AE SEM from six samples. In U2OS cells, the expression of FLAG-FKBP51 had no effect on proliferation ( Fig. 3a and Fig. S2b) . A confluent monolayer of U2OS cells was scratched, and cell motility was measured in a wound-healing assay using time-lapse microscopy ( Fig. 3b) . Phase contrast images are shown for 0 and 24 h. The dotted lines indicate cells at the start of the experiment, and white lines show the tips of migrated cells after 24 h. Bar graphs show the proportion of cell motility as the mean AE SEM from three samples (Fig. 3c) . U2OS cells transfected with FLAG-FKBP51 exhibited significantly increased motility relative to cells transfected with the FLAG-mock vector (P = 0.017, Student's t-test; n = 3). The ROCK inhibitor Y-27632 decreased cell motility (P < 0.01, Student's t-test; n = 4) (Fig. 3d) . Cell invasion was measured using the CytoSelect 96-well collagen I cell invasion assay (Cell Biolabs, San Diego, CA, USA). Invasive cells pass through the basement membrane layer, whereas noninvasive cells remain in the upper chamber. After removal of non-invasive cells, invading cells were stained and counted. Column graphs show the mean AE SEM from three samples (Fig. 3e) . Cell invasion was increased by overexpression of FLAG-FKBP51 (P = 0.034, Student's t-test; n = 3).
Knockdown of FKBP51 influences Rho-GAP activity. We assessed whether the knockdown of FKBP51 affects GAP activity. We knocked down FKBP51 expression in U2OS cells and examined the levels of GTP-RhoA using a pull-down assay. A Western blot analysis revealed that RhoA activity was decreased in FKBP51 siRNA-transfected cells compared with control siRNA-transfected cells (Fig. 4a,b) . Cells expressing FLAG-FKBP51 or Halo-DLC2 were visualized by antiHalo, anti-FKBP51 and anti-GAPDH antibodies (Fig. 4c) . These results indicate that knocking down of FKBP51 induces RhoA inactivation.
Knockdown of FKBP51 prevents cell motility and invasion. We next assessed whether the knockdown of FKBP51 inhibited cell motility and invasion. We treated U2OS cells with siRNA-FKBP51. FKBP51 knockdown did not affect cell proliferation for 72 h, as determined by the WST-1 assay (Fig. 5a and Fig. S3a) . Each sample was subjected to SDS-PAGE, followed by immunoblot analysis with anti-FKBP51 (Fig. S3b) . b-actin was used as a loading control. We compared the motility and invasion of U2OS cells treated with siRNA-FKBP51 to cells treated with the siRNA-control. Cell motility was measured in a wound-healing assay using time-lapse microscopy ( Fig. 5b) . Phase contrast images are shown for 0 and 24 h. Cells treated with siRNA-FKBP51 exhibited significantly reduced motility (Fig. 5c) and invasion (Fig. 5d) , compared with cells treated with the siRNA-control (motility; P = 0.031 [FKBP51-1 vs control] and 0.001 [FKBP51-2 vs control], Student's t-test; n = 3, invasion; P = 0.041 [FKBP51-1 vs control] and 0.0001 [FKBP51-2 vs control], Student's t-test; n = 4). These data demonstrate that FKBP51 plays a functional role in promoting cell motility and invasion.
Knockdown of FKBP51 prevents RhoA activity and alters the actin cytoskeleton. GTP-RhoA plays a key role in cytoskeleton reorganization and the formation of actin stress fibers. (33) Thus, we investigated whether the knockdown of FKBP51 altered the actin cytoskeleton, which was visualized by staining cells with phalloidin-ATTO565. siRNA control cells showed cytoplasmic bundles of actin fibers. By contrast, siRNA FKBP51-treated cells showed markedly reduced bundles and the cortical localization of F-actin ( Fig. 6a-c; panels   2, 4, and 6 ). The knockdown of FKBP51 showed the formation of lamellipodia visualized by cortactin staining (Fig. 6a,  b ; panels 1 and 3), unlike the siRNA control ( Fig. 6c; panel  5 ). The fraction of abnormal cells (exhibiting a collapse of F-actin fibers) was 69.6 AE 12.2% in the knockdown cells and 12.4 AE 6.6% in the control cells (Fig. 6e) . F-actin was quantified by measuring the intensity of phalloidin fluorescence using an EnSpire plate reader (PerkinElmer, Waltham, MA, USA). The fluorescence intensity of phalloidin-labeled actin was reduced in siRNA FKBP51-treated cells when compared with the siRNA control (Fig. 6f) . These results indicate that FKBP51 is required for the organization of the actin cytoskeleton.
ROCK activity in FLAG-FKBP51-expressing U2OS cells. To focus on the mechanism by which FKBP51 promotes in vitro cell motility and invasion of cancer cells, we investigated the potential downstream targets of Rho activity. There are two major effectors for Rho signaling, ROCK and mDia. The balance of these two signaling molecules determines stress fiber formation and membrane ruffles. Rho-mDia signaling produces membrane ruffles through Rac activation, and this signaling is suppressed by Rho-ROCK activity, which is required for stress fiber formation. To determine whether FKBP51 influences Rho-mDia or Rho-ROCK signaling, we assessed the formation of membrane ruffles and actin stress fiber by immunostaining with a cortactin antibody and phalloidin-ATTO565, respectively. We observed differences in the formation of membrane ruffles between FLAG-FKBP51-expressing U2OS cells and mock-treated cells (Fig. 7a) . FLAG-FKBP51-expressing cells showed decreased membrane ruffles when compared with mock-treated cells. To investigate whether FKBP51 overexpression altered Rho-ROCK activity, ROCK1 protein was fractionated with anion-exchange chromatography (Fig. 7b) . The expression of FLAG-FKBP5 significantly activated ROCK activity in an immunoblot assay, and this effect was attenuated by a specific ROCK inhibitor Y27632 and a lack of ATP (Fig. 7c , n = 3, P < 0.05).
Discussion
In this study, we discovered a new molecular pathway for the regulation of RhoA activity. Specifically, FKBP51-deficient cells contained a disrupted cytoskeleton with altered actin stress fibers (Fig. 6 ). Actin stress fibers can be divided into three different classes based on their subcellular location and role in cell motility: ventral stress fibers, dorsal stress fibers, and transvers arcs. (34) Ventral stress fibers are part of the major contractile machinery in many interphase cells and lie along the base of the cell. (34) Transverse arcs are actin filament bundles that form a periodic actinin-myosin II pattern and convey contractile force to the surrounding environment through their connections with dorsal stress fibers. (35) The formation of ventral stress fibers, dorsal stress fibers, and transvers arcs were inhibited in FKBP51-deficient cells compared to in siRNA control-treated cells (Fig. 6a-d) .
Our study revealed that the overexpression of FKBP51 led to a significant increase in RhoA activation (Fig. 2) and cell motility (Fig. 3) , compared with controls, suggesting that the GAP activity of DLC1/2 may be inhibited by FKBP51. Treatment with siRNA-DLC2 increased wound healing and cell motility in MCF7 cells (36) and increased migration in human endothelial cells. These effects were attenuated by silencing RhoA. (37) DLC1 loss is sufficient to promote migratory behavior in breast cancer cells. (38) A RhoA pull-down assay demonstrated a remarkable reduction in RhoA activity in transiently DLC2-transfected cells. (20) Furthermore, the formation of actin stress fibers in DLC2-GAP expressing cells was significantly inhibited compared with in non-transfected cells. (24) In our current study, the knockdown of FKBP51 significantly decreased RhoA activation (Fig. 4 ) and cell motility (Fig. 5 ), but did not influence DLC1/2 expression (data not shown), when compared with the control, suggesting that the GAP activity of DLC1/2 is enhanced by the silencing of endogenous FKBP51. Among Rho effectors, the role of ROCK and mDia in stress fiber formation is well documented. ROCK is a major mediator of Rho-mediated actin cytoskeletal structures, including stress fibers, whereas mDia catalyzes actin nucleation and polymerization. (39, 40) ROCK and mDia antagonize each other during Rho-dependent Rac activation, and the balance of these two pathways determines the pattern of stress fibers. (41) A recent study revealed that active RhoA-Rhotekin and S100A4 forms a complex; however, the role of Rhotekin in Rho-mediated downstream signal transduction leading to actin cytoskeleton reorganization remains largely unknown. (42) In this study, we investigated the potential downstream targets of RhoA activity induced by the overexpression of FKBP51. Our results showed that ROCK activity was enhanced by the expression of FLAG-FKBP51. Thus, FKBP51 overexpression promotes Rho-ROCK signaling over Rho-mDia signaling, which leads to the formation of actin stress fibers.
Our results suggest that FKBP51 affects GAP activity. The underlying mechanism by which FKBP51 inhibits GAP activity remains unclear. However, we identified DLC1 and DLC2 from immunoprecipitation with an anti-FKBP51 antibody and subsequent mass spectroscopy (Fig. 1, Fig. S1 ). Association with 14-3-3 proteins inhibits DLC1 GAP activity and facilitates Rho signaling. (43) Protein kinase D (PKD) stimulates the association of DLC1 with the phosphoserine-binding 14-3-3 proteins through recognition motifs that include Ser327 and Ser431. (43) We identified PKD in our immunoprecipitation experiments with an anti-FKBP51 antibody (data not shown). Thus, FKBP51 may be involved in the regulation of PKDmediated DLC1 phosphorylation (Ser327 and Ser431). The inhibitory mechanism of GAP activity via FKBP51 requires further study. Moreover, investigating whether FKBP51 directly binds to the GAP domain of DLC1/2 may reveal the mechanism for its inhibitory effect on GAP activity. These results raise the interesting possibility that FKBP51 is associated with metastatic migration and the invasion of tumor cells via a novel RhoA-based pathway. In addition, we would argue that the high expression of FKBP51 in several cancer cells gives rise to metastatic potential.
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